MCID: SRC025
MIFTS: 61

Sarcoidosis 1

Categories: Genetic diseases, Rare diseases, Immune diseases, Neuronal diseases, Eye diseases, Nephrological diseases, Respiratory diseases, Bone diseases, Endocrine diseases

Aliases & Classifications for Sarcoidosis 1

MalaCards integrated aliases for Sarcoidosis 1:

Name: Sarcoidosis 1 54 71
Sarcoidosis 12 50 56 71 52 41 42 14 69
Boeck Sarcoid 12 56 71
Besnier-Boeck-Schaumann Disease 56 71
Sarcoidosis, Susceptibility to, 1 13
Lymphogranulomatosis 12
Schaumann's Disease 50
Sarcoid of Boeck 50
Hodgkin Disease 69
Boeck's Sarcoid 56
Ss1 71

Characteristics:

Orphanet epidemiological data:

56
sarcoidosis
Inheritance: Multigenic/multifactorial; Prevalence: 1-5/10000 (Worldwide),1-5/10000 (Europe); Age of onset: Adult;

OMIM:

54
Inheritance:
isolated cases

Miscellaneous:
onset usually before age 40 years
systemic granulomatous disease
generalized fatigue
u.s. frequency higher in blacks than whites


HPO:

32
sarcoidosis 1:
Inheritance sporadic


Classifications:



Summaries for Sarcoidosis 1

NIH Rare Diseases : 50 sarcoidosis is an inflammatory disease characterized by the development and growth of tiny lumps of cells called granulomas. if these tiny granulomas grow and clump together in an organ, they can affect the organ's structure and function. overtime, this can lead to permanent scarring or thickening of the organ tissue (also called fibrosis). although the granulomas can be found in almost any part of the body, they occur most commonly in the lungs and lymph nodes. signs and symptoms of sarcoidosis vary based on the location of the granulomas and the severity of the condition. the exact cause of sarcoidosis is poorly understood. in many cases, treatment is not necessary and sarcoidosis will resolve on its own. however, therapies such as corticosteroids, immunosuppressants, and antimalarial drugs, are available to control symptoms, prevent complications, and improve outcomes. last updated: 4/16/2017

MalaCards based summary : Sarcoidosis 1, also known as sarcoidosis, is related to lymphoma and sarcoidosis 2, and has symptoms including nephrolithiasis, nephrocalcinosis and hypercalciuria. An important gene associated with Sarcoidosis 1 is HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dexmedetomidine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and lymph node, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

UniProtKB/Swiss-Prot : 71 Sarcoidosis 1: An idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved.

MedlinePlus : 41 sarcoidosis is a disease that leads to inflammation, usually in your lungs, skin, or lymph nodes. it starts as tiny, grain-like lumps, called granulomas. sarcoidosis can affect any organ in your body. no one is sure what causes sarcoidosis. it affects men and women of all ages and races. it occurs mostly in people ages 20 to 50, african americans, especially women, and people of northern european origin. many people have no symptoms. if you have symptoms, they may include cough shortness of breath weight loss night sweats fatigue tests to diagnose sarcoidosis include chest x-rays, lung function tests, and a biopsy. not everyone who has the disease needs treatment. if you do, prednisone, a type of steroid, is the main treatment. nih: national heart, lung, and blood institute

OMIM : 54
Idiopathic scoliosis is a structurally fixed lateral curvature of the spine with a rotatory component. There is at least a 10 degree curvature as demonstrated by upright spine roentgenograms by the Cobb method (Weinstein, 1994). (181000)

Disease Ontology : 12 A hypersensitivity reaction type IV disease characterized by the growth of collections of inflammatory cells (granulomas) in multiple organs.

Related Diseases for Sarcoidosis 1

Diseases in the Sarcoidosis 1 family:

Sarcoidosis 2 Sarcoidosis 3

Diseases related to Sarcoidosis 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
id Related Disease Score Top Affiliating Genes
1 lymphoma 30.7 ACE IFNG IL1B TNF
2 sarcoidosis 2 11.1
3 angioimmunoblastic t-cell lymphoma 11.0
4 neuromuscular disease 10.9 ACE NOD2 TNF
5 mosaic trisomy 1 10.9 HLA-DRB1 IFNG TNF
6 lymphocytic colitis 10.9 HLA-DRB1 IFNG TNF
7 not otherwise specified 3-mga-uria type 10.9 HLA-DRB1 SLC11A1 TNF
8 autoimmune retinopathy 10.9 HLA-DRB1 IL2RA TNF
9 hepadnavirus infection 10.9 HLA-DRB1 IFNG TNF
10 crohn's colitis 10.9 IL2RA NOD2 TNF
11 pericardium disease 10.9 ACE HLA-DRB1 TNF
12 alport syndrome-intellectual disability-midface hypoplasia-elliptocytosis syndrome 10.9 HLA-DRB1 IL2RA SLC11A1
13 deafness, autosomal recessive 67 10.8 IL18 NOD2 TNF
14 disease of mental health 10.8 HLA-DRB1 IFNG TNF
15 extrahepatic bile duct adenocarcinoma 10.8 HLA-DRB1 IFNG TNF
16 central nervous system leiomyosarcoma 10.8 HLA-DRB1 IL1B TNF
17 eye accommodation disease 10.8 IFNG IL2RA
18 parametritis 10.8 IFNG IL2RA TNF
19 sternal cleft 10.8 IFNG IL1B TNF
20 dentinogenesis imperfecta 10.8 HLA-DRB1 IFNG TNF
21 pasteurellosis 10.8 IFNG SCGB1A1 TNF
22 cryptogenic late-onset epileptic spasms 10.8 ACE TNF
23 tabatznik syndrome 10.8 IL18 IL1B TNF
24 reardon wilson cavanagh syndrome 10.8 IFNG IL18 TNF
25 atypical lichen myxedematosus 10.8 CXCR3 IL2RA TNF
26 foodborne botulism 10.8 BTNL2 IL1B TNF
27 ethmoid sinus adenocarcinoma 10.8 IL12RB1 SLC11A1 TNF
28 patau syndrome 10.8 HLA-DRB1 IL1B TNF
29 early-onset zonular cataract 10.8 IFNG IL1B TNF
30 yao syndrome 10.8 IL1B NOD2 TNF
31 female reproductive system disease 10.8 IL12RB1 NOD2 TNF
32 melioidosis 10.8 IFNG IL18 TNF
33 ethmoid sinus cancer 10.8 IFNG IL1B SLC11A1
34 gastric ulcer 10.8 CHIT1 IFNG TNF
35 senile reticular retinal degeneration 10.8 IFNG IL1B TNF
36 islet cell tumor 10.8 ACE CCL2 TNF
37 leptospirosis 10.8 IL12RB1 NOD2 TNF
38 cardiac sarcoidosis 10.8 ACE TNF
39 kernicterus due to isoimmunization 10.8 HLA-DRB1 LTA TNF
40 bartonellosis 10.8 IFNG IL1B TNF
41 erythema infectiosum 10.8 IFNG IL18 TNF
42 dengue disease 10.7 IFNG SLC11A1 TNF
43 mucocutaneous leishmaniasis 10.7 IFNG SLC11A1 TNF
44 spindle cell hemangioma 10.7 ICAM1 IFNG TNF
45 cauda equina syndrome 10.7 IL18 LTA TNF
46 dermatitis herpetiformis, familial 10.7 CCL2 HLA-DRB1 IFNG
47 left bundle branch hemiblock 10.7 HLA-DRB1 IFNG IL2RA TNF
48 biemond syndrome 10.7 HLA-DRB1 TNF
49 conduct disorder 10.7 ICAM1 IFNG TNF
50 autoimmune polyglandular syndrome type 3 10.7 IFNG TNF

Graphical network of the top 20 diseases related to Sarcoidosis 1:



Diseases related to Sarcoidosis 1

Symptoms & Phenotypes for Sarcoidosis 1

Symptoms via clinical synopsis from OMIM:

54

Laboratory- Abnormalities:
hypercalciuria
elevated erythrocyte sedimentation rate (esr)
elevated serum angiotensin-converting enzyme (ace)
positive kveim-siltzbach skin test
mononuclear cell noncaseating granulomatous inflammation on biopsy (lung, skin, lip)

Respiratory:
dyspnea
cough

Growth- Weight:
weight loss

Hematology:
bone marrow involvement may cause pancytopenia

Abdomen- Liver:
hepatomegaly may occur
elevated liver function tests may occur

Abdomen- Gastroin testinal:
anorexia
associated inflammatory bowel disease

Neurologic- Central Nervous System:
neurosarcoidosis (5-16% of patients)

Head And Neck- Eyes:
glaucoma
photophobia
blurred vision
uveitis
enlarged lacrimal glands
more
Metabolic Features:
fever

Respiratory- Lung:
bilateral hilar adenopathy
pulmonary parenchymal infiltration
pulmonary function tests show interstitial lung disease

Head And Neck- Mouth:
enlarged salivary glands

Abdomen- Spleen:
splenomegaly may occur

Skeletal:
polyarthritis
bone cysts

Immunology:
activated t-helper cells
activated mononuclear phagocytes
exaggerated cellular immune processes
hyperglobulinemia
generalized lymphadenopathy


Clinical features from OMIM:

181000

Human phenotypes related to Sarcoidosis 1:

56 32 (show top 50) (show all 91)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nephrolithiasis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000787
2 nephrocalcinosis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000121
3 hypercalciuria 56 32 occasional (7.5%) Occasional (29-5%) HP:0002150
4 hepatomegaly 56 32 occasional (7.5%) Occasional (29-5%) HP:0002240
5 thrombocytopenia 56 32 frequent (33%) Frequent (79-30%) HP:0001873
6 leukopenia 56 32 frequent (33%) Frequent (79-30%) HP:0001882
7 peripheral neuropathy 56 32 occasional (7.5%) Occasional (29-5%) HP:0009830
8 alopecia 56 32 occasional (7.5%) Occasional (29-5%) HP:0001596
9 glaucoma 56 32 occasional (7.5%) Occasional (29-5%) HP:0000501
10 fatigue 56 32 frequent (33%) Frequent (79-30%) HP:0012378
11 renal insufficiency 56 32 occasional (7.5%) Occasional (29-5%) HP:0000083
12 blindness 56 32 occasional (7.5%) Occasional (29-5%) HP:0000618
13 cataract 56 32 occasional (7.5%) Occasional (29-5%) HP:0000518
14 hemolytic anemia 56 32 very rare (1%) Very rare (<4-1%) HP:0001878
15 eosinophilia 56 32 very rare (1%) Very rare (<4-1%) HP:0001880
16 dyspnea 56 32 frequent (33%) Frequent (79-30%) HP:0002094
17 tubulointerstitial nephritis 56 32 occasional (7.5%) Occasional (29-5%) HP:0001970
18 fever 56 32 frequent (33%) Frequent (79-30%) HP:0001945
19 increased csf protein 56 32 occasional (7.5%) Occasional (29-5%) HP:0002922
20 hepatic failure 56 32 occasional (7.5%) Occasional (29-5%) HP:0001399
21 cough 56 32 frequent (33%) Frequent (79-30%) HP:0012735
22 portal hypertension 56 32 occasional (7.5%) Occasional (29-5%) HP:0001409
23 lymphadenopathy 56 32 occasional (7.5%) Occasional (29-5%) HP:0002716
24 hypercalcemia 56 32 occasional (7.5%) Occasional (29-5%) HP:0003072
25 hyperthyroidism 56 32 very rare (1%) Very rare (<4-1%) HP:0000836
26 proximal muscle weakness 56 32 occasional (7.5%) Occasional (29-5%) HP:0003701
27 hypothyroidism 56 32 very rare (1%) Very rare (<4-1%) HP:0000821
28 bronchiectasis 56 32 occasional (7.5%) Occasional (29-5%) HP:0002110
29 diabetes insipidus 56 32 occasional (7.5%) Occasional (29-5%) HP:0000873
30 weight loss 56 32 frequent (33%) Frequent (79-30%) HP:0001824
31 hypothermia 56 32 very rare (1%) Very rare (<4-1%) HP:0002045
32 hemoptysis 56 32 very rare (1%) Very rare (<4-1%) HP:0002105
33 heart block 56 32 occasional (7.5%) Occasional (29-5%) HP:0012722
34 chest pain 56 32 frequent (33%) Frequent (79-30%) HP:0100749
35 pulmonary fibrosis 56 32 occasional (7.5%) Occasional (29-5%) HP:0002206
36 dacryocystitis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000620
37 upper airway obstruction 56 32 occasional (7.5%) Occasional (29-5%) HP:0002781
38 joint swelling 56 32 frequent (33%) Frequent (79-30%) HP:0001386
39 facial palsy 56 32 occasional (7.5%) Occasional (29-5%) HP:0010628
40 scarring 56 32 occasional (7.5%) Occasional (29-5%) HP:0100699
41 uveitis 56 32 frequent (33%) Frequent (79-30%) HP:0000554
42 erythema nodosum 56 32 frequent (33%) Frequent (79-30%) HP:0012219
43 enlarged lacrimal glands 56 32 occasional (7.5%) Occasional (29-5%) HP:0007734
44 emphysema 56 32 occasional (7.5%) Occasional (29-5%) HP:0002097
45 keratoconjunctivitis sicca 56 32 occasional (7.5%) Occasional (29-5%) HP:0001097
46 pneumothorax 56 32 occasional (7.5%) Occasional (29-5%) HP:0002107
47 chylothorax 56 32 occasional (7.5%) Occasional (29-5%) HP:0010310
48 ventricular tachycardia 56 32 occasional (7.5%) Occasional (29-5%) HP:0004756
49 subcutaneous nodule 56 32 occasional (7.5%) Occasional (29-5%) HP:0001482
50 abnormality of the gastrointestinal tract 56 32 occasional (7.5%) Occasional (29-5%) HP:0011024

UMLS symptoms related to Sarcoidosis 1:


coughing, snoring

GenomeRNAi Phenotypes related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 TNF ICAM1 IL18 IL1B IL2RA LTA
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 ICAM1 IL18 IL1B IL2RA LTA NOD2

MGI Mouse Phenotypes related to Sarcoidosis 1:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 IL1B IL2RA LTA MIF NOD2 SLC11A1
2 homeostasis/metabolism MP:0005376 9.97 ACE CXCR3 ICAM1 IFNG IL12RB1 IL18
3 immune system MP:0005387 9.86 CHIT1 CXCR3 ICAM1 IFNG IL12RB1 IL18
4 neoplasm MP:0002006 9.28 ACE CXCR3 ICAM1 IFNG IL1B MIF

Drugs & Therapeutics for Sarcoidosis 1

Drugs for Sarcoidosis 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 203)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
2
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
3
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
4 Racepinephrine Approved Phase 4
5
Remifentanil Approved Phase 4 132875-61-7 60815
6
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
7
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
8
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
9
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
10
Interferon beta-1a Approved, Investigational Phase 4,Phase 3 145258-61-3 6438354
11
Nicotine Approved Phase 4,Phase 1,Phase 2 54-11-5 942 89594
12
Acetylcholine Approved Phase 4 51-84-3 187
13
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
14
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-30-3 6037
16
leucovorin Approved, Nutraceutical Phase 4,Phase 1 58-05-9 143 6006
17 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1
18 Adrenergic Agonists Phase 4,Phase 1,Phase 2
19 Adrenergic alpha-2 Receptor Agonists Phase 4
20 Adrenergic alpha-Agonists Phase 4,Phase 1,Phase 2
21 Analgesics Phase 4,Phase 2
22 Analgesics, Non-Narcotic Phase 4,Phase 2
23 Analgesics, Opioid Phase 4
24 Anesthetics Phase 4,Phase 2,Phase 3
25 Anesthetics, General Phase 4
26 Anesthetics, Intravenous Phase 4
27 Central Nervous System Depressants Phase 4,Phase 2,Phase 3
28 Epinephryl borate Phase 4
29 Hypnotics and Sedatives Phase 4
30 Narcotics Phase 4
31 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Antiemetics Phase 4,Phase 3
35 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Gastrointestinal Agents Phase 4,Phase 3
37 glucocorticoids Phase 4,Phase 3
38 Hormone Antagonists Phase 4,Phase 3,Phase 2
39 Hormones Phase 4,Phase 3,Phase 2
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
41 Platelet Aggregation Inhibitors Phase 4
42 Vasodilator Agents Phase 4,Phase 1
43 Antimetabolites Phase 4,Phase 2
44 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Dermatologic Agents Phase 4,Phase 2
46 Folic Acid Antagonists Phase 4,Phase 1
47 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Methylprednisolone acetate Phase 4
49 Methylprednisolone Hemisuccinate Phase 4
50 Neuroprotective Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 96)

id Name Status NCT ID Phase Drugs
1 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
2 Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension Completed NCT00403650 Phase 4 Iloprost
3 Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) Active, not recruiting NCT01830959 Phase 4 Roflumilast;Placebo
4 Study of Nicotine Patches in Patients With Sarcoidosis Suspended NCT00701207 Phase 4 nicotine patch
5 Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis Terminated NCT00918554 Phase 4 Methotrexate;Placebo
6 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
7 Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects Withdrawn NCT00101959 Phase 4 Rebif
8 Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis Unknown status NCT01920919 Phase 3 Dexamethasone;Placebo
9 ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study Unknown status NCT02155803 Phase 2, Phase 3 ACTHAR Gel (adrenocorticotropic hormone)
10 Interferon ß-1b Treatment by Cyclical Administration Completed NCT00270816 Phase 2, Phase 3 Interferon-ß-1b;Interferon ß-1b
11 Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension Completed NCT00581607 Phase 2, Phase 3 Bosentan;Placebo;Bosentan;Placebo
12 A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy Completed NCT01955824 Phase 2, Phase 3 1% lignocaine;2% lignocaine
13 Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease) Completed NCT01052428 Phase 2, Phase 3 metoprolol succinate (Toprol XL);Placebo
14 Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase Completed NCT00340834 Phase 3 Fingolimod 1.25 mg;Fingolimod 0.5 mg;Interferon β-1a 30 µg
15 Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis Completed NCT00906399 Phase 3 BIIB017 (peginterferon beta-1a);Placebo
16 SARCOTHAL. Thalidomide in Skin Sarcoidosis Completed NCT00305552 Phase 3 THALIDOMIDE
17 Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). Completed NCT02200146 Phase 3 Prednisone;Hydroxychloroquine + Prednisone
18 Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection Completed NCT02023099 Phase 3 ABT-450/r/ABT-267;Placebo
19 Antibody Response to Influenza Vaccine in Patients With Sarcoidosis Completed NCT00828828 Phase 3
20 Mycophenolate for Pulmonary Sarcoidosis Terminated NCT00262132 Phase 3 Mycophenolate
21 A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Withdrawn NCT01975298 Phase 3 Laquinimod;Avonex®
22 A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome Unknown status NCT02464319 Phase 2 hrIL-2 active;hrIL-2 placebo
23 Effects of Adrenergic Drugs on the Fluid Balance During Surgery Completed NCT01431612 Phase 1, Phase 2 Esmolol administration;Phenylephrine infusion;Lactated Ringer´s solution
24 Trial of Antimycobacterial Therapy in Sarcoidosis Completed NCT01074554 Phase 1, Phase 2 Antibiotic Regimen;Placebo Regimen
25 Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis Completed NCT02039687 Phase 2 ARA 290
26 Rituximab for Pulmonary Sarcoidosis Completed NCT00855205 Phase 2 Rituximab
27 A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis Completed NCT00955279 Phase 2 Placebo;Golimumab;Ustekinumab
28 Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV Completed NCT02690103 Phase 2 pegylated IFN;Ribavirin
29 A Study of Adalimumab to Treat Sarcoidosis of the Skin Completed NCT00274352 Phase 2 adalimumab
30 Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome Recruiting NCT02110446 Phase 2 SS-1;Placebo
31 Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome Recruiting NCT02855658 Phase 2 SS-1;Placebo
32 Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis Recruiting NCT02888080 Phase 2 ACZ885;Placebo
33 Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study Recruiting NCT02265874 Phase 1, Phase 2 Habitrol;Placebo to Habitrol
34 Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 Recruiting NCT03048097 Phase 2 Fluorodeoxyglucose;Rubidium
35 Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis Recruiting NCT02024555 Phase 2 Levofloxacin;Ethambutol;Azithromycin;Rifampin;Placebo
36 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Active, not recruiting NCT01362790 Phase 1, Phase 2 Pentostatin;Cyclophosphamide
37 Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability Suspended NCT01615484 Phase 2
38 Safety and Efficacy Study of Bosentan in Progressive Pulmonary Sarcoidosis Terminated NCT00926627 Phase 2 bosentan;placebo
39 Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis Terminated NCT00282438 Phase 1, Phase 2
40 Safety Study of Abatacept to Treat Refractory Sarcoidosis Terminated NCT00739960 Phase 2 Abatacept
41 A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis Terminated NCT01732211 Phase 2
42 Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis Withdrawn NCT00731757 Phase 2 Humira
43 Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis Withdrawn NCT00690911 Phase 2 adalimumab
44 A Phase 2 Study With CC-220 in Skin Sarcoidosis Withdrawn NCT02192489 Phase 2 CC-220 0.3 mg Daily;CC-220 0.6mg Daily;Placebo
45 SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma Completed NCT01445392 Phase 1 Pemetrexed;Cisplatin
46 A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma Completed NCT01051934 Phase 1 SS1 (dsFv) PE38;Paclitaxel;Carboplatin;Bevacizumab
47 Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide Completed NCT01043146 Phase 1 COR-1;placebo
48 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
49 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
50 Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis Completed NCT01169038 Phase 1 levaquin; ethambutol; rifampin and azithromycin.

Search NIH Clinical Center for Sarcoidosis 1

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: sarcoidosis

Genetic Tests for Sarcoidosis 1

Anatomical Context for Sarcoidosis 1

MalaCards organs/tissues related to Sarcoidosis 1:

39
Lung, Skin, Lymph Node, Testes, Liver, Heart, Eye

Publications for Sarcoidosis 1

Articles related to Sarcoidosis 1:

id Title Authors Year
1
Sarcoidosis. 1. ( 5059500 )
1972
2
Pulmonary sarcoidosis. 1. Pathophysiologic correlations. ( 5649858 )
1968
3
Sarcoidosis. 1. Ultrastructural investigations on epithelioid cell granulomas. ( 5955900 )
1966

Variations for Sarcoidosis 1

ClinVar genetic disease variations for Sarcoidosis 1:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 HLA-DRB1 HLA-DRB1, HLA-DRB1*1101 undetermined variant risk factor

Expression for Sarcoidosis 1

Search GEO for disease gene expression data for Sarcoidosis 1.

Pathways for Sarcoidosis 1

Pathways related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 BTNL2 CCL2 CCL3 CHIT1 HLA-DRB1 ICAM1
2
Show member pathways
13.89 CCL2 CCL3 CXCL9 CXCR3 IL12RB1 IL18
3
Show member pathways
13.72 CCL2 CCL3 CXCL9 CXCR3 IFNG IL12RB1
4
Show member pathways
13.6 CCL2 CCL3 ICAM1 IFNG IL12RB1 IL18
5
Show member pathways
13.49 CCL2 CCL3 CXCL9 CXCR3 IL12RB1 IL18
6
Show member pathways
13.38 CCL2 CCL3 CXCL9 CXCR3 IL12RB1 IL18
7
Show member pathways
13.32 CCL2 CCL3 HLA-DRB1 ICAM1 IFNG IL12RB1
8
Show member pathways
12.97 ACE CCL2 CCL3 CXCL9 IFNG IL1B
9
Show member pathways
12.93 CXCL9 HLA-DRB1 ICAM1 IFNG IL1B IL2RA
10
Show member pathways
12.8 CCL2 HLA-DRB1 ICAM1 IFNG IL18 IL1B
11
Show member pathways
12.71 HLA-DRB1 IFNG IL12RB1 IL18 IL2RA TNF
12
Show member pathways
12.68 CCL2 CXCL9 IFNG IL12RB1 IL18 IL1B
13
Show member pathways
12.65 HLA-DRB1 IFNG IL12RB1 IL18 IL1B IL2RA
14 12.59 CCL2 IFNG IL1B IL2RA TNF
15 12.5 HLA-DRB1 ICAM1 IL2RA LTA TNF
16
Show member pathways
12.35 CCL2 IFNG IL1B TNF
17 12.32 HLA-DRB1 IFNG IL18 IL1B NOD2 TNF
18
Show member pathways
12.3 IFNG IL1B MIF TNF
19
Show member pathways
12.29 HLA-DRB1 IFNG IL1B TNF
20
Show member pathways
12.26 IFNG IL18 IL1B LTA TNF
21 12.2 CCL2 ICAM1 IFNG IL1B TNF
22 12.11 CCL2 ICAM1 IFNG IL1B MIF TNF
23 12.1 CCL2 ICAM1 IL18 IL1B TNF
24
Show member pathways
12.09 CCL2 CCL3 CXCL9 CXCR3
25 12.05 CCL2 ICAM1 IL1B LTA NOD2 TNF
26
Show member pathways
12.03 IFNG IL12RB1 IL18 IL1B LTA TNF
27 11.99 CCL2 ICAM1 IL1B TNF
28 11.97 HLA-DRB1 IL1B IL2RA TNF
29
Show member pathways
11.97 CCL3 HLA-DRB1 IFNG IL12RB1 IL18 IL1B
30 11.96 ICAM1 IL1B LTA TNF
31 11.91 CCL3 IFNG IL18 IL1B
32 11.81 ICAM1 IL2RA LTA TNF
33
Show member pathways
11.78 IFNG IL2RA TNF
34 11.78 IFNG IL1B TNF
35
Show member pathways
11.77 ICAM1 IFNG IL1B MIF TNF
36 11.76 CCL2 CCL3 IL1B TNF
37
Show member pathways
11.68 IFNG IL2RA TNF
38 11.63 IL18 IL1B TNF
39 11.63 CCL2 IFNG IL18 IL1B TNF
40
Show member pathways
11.58 IFNG LTA TNF
41 11.56 IFNG IL1B TNF
42
Show member pathways
11.54 CCL3 IFNG IL2RA TNF
43 11.53 IFNG IL1B TNF
44 11.51 CXCL9 ICAM1 IFNG IL1B
45 11.51 CCL2 CCL3 HLA-DRB1 ICAM1 IFNG IL18
46 11.49 IL18 IL1B NOD2
47 11.49 CCL2 CCL3 ICAM1 IL18 IL1B TNF
48 11.43 IFNG IL18 IL1B TNF
49 11.42 ICAM1 IFNG IL18 IL1B TNF
50 11.42 CCL2 ICAM1 IFNG IL18 IL1B TNF

GO Terms for Sarcoidosis 1

Cellular components related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 ACE CCL2 CCL3 CHIT1 CXCL9 IFNG
2 cell surface GO:0009986 9.8 CXCR3 HLA-DRB1 ICAM1 IL2RA MIF NOD2
3 extracellular space GO:0005615 9.77 ACE CCL2 CCL3 CHIT1 CXCL9 ICAM1
4 lysosome GO:0005764 9.72 ACE CHIT1 HLA-DRB1 IL1B SLC11A1
5 external side of plasma membrane GO:0009897 9.28 ACE CXCL9 CXCR3 HLA-DRB1 ICAM1 IFNG

Biological processes related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
id Name GO ID Score Top Affiliating Genes
1 chemotaxis GO:0006935 9.99 CCL2 CCL3 CXCL9 CXCR3
2 MAPK cascade GO:0000165 9.99 CCL2 CCL3 IL18 IL1B IL2RA TNF
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 ICAM1 IL1B NOD2 TNF
4 cellular response to lipopolysaccharide GO:0071222 9.96 CCL2 ICAM1 IFNG TNF
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 CCL2 CCL3 ICAM1 MIF NOD2 TNF
6 cellular response to interleukin-1 GO:0071347 9.91 CCL2 CCL3 ICAM1
7 negative regulation of gene expression GO:0010629 9.91 CCL3 IFNG MIF TNF
8 response to lipopolysaccharide GO:0032496 9.91 CCL2 CXCL9 ICAM1 IL1B LTA SCGB1A1
9 positive regulation of JNK cascade GO:0046330 9.9 IL1B NOD2 TNF
10 interferon-gamma-mediated signaling pathway GO:0060333 9.9 HLA-DRB1 ICAM1 IFNG
11 response to glucocorticoid GO:0051384 9.9 CCL2 SCGB1A1 TNF
12 regulation of insulin secretion GO:0050796 9.9 IFNG IL1B TNF
13 chemokine-mediated signaling pathway GO:0070098 9.9 CCL2 CCL3 CXCL9 CXCR3
14 neutrophil chemotaxis GO:0030593 9.88 CCL2 CCL3 IFNG IL1B
15 positive regulation of cell adhesion GO:0045785 9.87 CCL2 IFNG TNF
16 positive regulation of interleukin-6 production GO:0032755 9.87 IL1B NOD2 TNF
17 positive regulation of T cell proliferation GO:0042102 9.87 BTNL2 IFNG IL1B IL2RA
18 cellular response to interferon-gamma GO:0071346 9.86 CCL2 CCL3 ICAM1 IL12RB1
19 humoral immune response GO:0006959 9.85 CCL2 IFNG LTA TNF
20 negative regulation of T cell proliferation GO:0042130 9.84 HLA-DRB1 IL2RA SCGB1A1
21 response to bacterium GO:0009617 9.83 CCL2 CHIT1 SLC11A1
22 positive regulation of phagocytosis GO:0050766 9.82 IL1B SLC11A1 TNF
23 positive regulation of activated T cell proliferation GO:0042104 9.82 IL12RB1 IL18 IL2RA
24 positive regulation of interleukin-8 production GO:0032757 9.81 IL1B NOD2 TNF
25 positive regulation of interleukin-1 beta secretion GO:0050718 9.81 CCL3 IFNG NOD2
26 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 ICAM1 IFNG IL1B TNF
27 positive regulation of NF-kappaB import into nucleus GO:0042346 9.79 IL18 IL1B TNF
28 protein kinase B signaling GO:0043491 9.78 CCL2 CCL3 IL1B TNF
29 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.77 IFNG IL1B TNF
30 negative regulation of growth of symbiont in host GO:0044130 9.76 IFNG LTA TNF
31 macrophage chemotaxis GO:0048246 9.74 CCL2 CCL3
32 positive regulation of interleukin-17 production GO:0032740 9.74 IL18 NOD2
33 inflammatory response to antigenic stimulus GO:0002437 9.74 HLA-DRB1 IL2RA
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.74 IL1B TNF
35 T-helper 1 type immune response GO:0042088 9.74 HLA-DRB1 IL18
36 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.73 IL18 IL1B
37 cellular response to organic cyclic compound GO:0071407 9.73 CCL2 CCL3 IL18 IL1B NOD2 TNF
38 regulation of defense response to virus by host GO:0050691 9.72 IFNG IL1B
39 detection of bacterium GO:0016045 9.72 HLA-DRB1 NOD2
40 positive regulation of T-helper 1 type immune response GO:0002827 9.72 IL12RB1 SLC11A1
41 lipopolysaccharide-mediated signaling pathway GO:0031663 9.72 CCL2 CCL3 IL18 IL1B TNF
42 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.71 IFNG IL1B
43 regulation of establishment of endothelial barrier GO:1903140 9.71 IL1B TNF
44 positive regulation of dendritic cell antigen processing and presentation GO:0002606 9.71 NOD2 SLC11A1
45 receptor-mediated virion attachment to host cell GO:0046813 9.71 ACE ICAM1
46 T cell chemotaxis GO:0010818 9.71 CCL3 CXCL9 CXCR3
47 positive regulation of tumor necrosis factor production GO:0032760 9.71 CCL2 CCL3 IFNG NOD2
48 positive regulation of cellular extravasation GO:0002693 9.7 CCL2 ICAM1
49 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.7 ICAM1 TNF
50 astrocyte cell migration GO:0043615 9.7 CCL2 CCL3

Molecular functions related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.28 CCL2 CCL3 CXCL9 IFNG IL18 IL1B
2 chemokine activity GO:0008009 9.13 CCL2 CCL3 CXCL9

Sources for Sarcoidosis 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....